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CORRESPONDENCE
Letters to the Editor
Visipaque (Iodixanol)
and Hexabrix (Ioxaglate)
in Renal Insufficiency
I read with great interest the RECOVER (Renal Toxicity Eval-
uation and Comparison Between Visipaque and Hexabrix in
Patients With Renal Insufficiency Undergoing Coronary Angiog-
raphy) study by Jo et al. (1). They compared the renal tolerance of
iodixanol and ioxaglate in patients with renal insufficiency after
coronary angiography. They found that the incidence of contrast-
induced nephropathy (CIN) was lower in the iodixanol group
(7.9%) as compared with the ioxaglate group (17%) (p  0.021).
I would be interested in obtaining some details as to why
substantial differences exist in the number of patients presented in
different meetings (n 281) (2,3) and in the final publication (n
275). In this regard, I also do not understand how 164 and 117
patients for the iodixanol and the ioxaglate groups, respectively,
may have been presented in previous meetings while the plan’s
sample size was 150 patients in each group with a permuted
block-randomization method.
Also, an intention-to-treat analysis would seem more appropriate
than a per-protocol analysis. Furthermore, among risk factors that
might have influenced the results, age (4) and hydration status (5,6)
are crucial. Patients were older in the ioxaglate group (68.7 7.5 years
vs. 66.1  8.6 years; p  0.01). Although the investigators indicate
that the difference is likely to be too small to be relevant it may still
represent a bias that may explain at least partially their results. Volume
supplementation remains the cornerstone for the prevention of CIN.
Hydration status was not assessed and/or not presented. Body weight,
diuresis, and volume given to the patients should be indicated to
ensure comparability between groups.
Finally, CIN remains a major health issue. Only one study (7) has
shown in diabetic patients with renal insufficiency that iodixanol is
less nephrotoxic than iohexol. Further trials should be conducted
to assess the comparative renal tolerance of low osmolar contrast
media (both ionic and nonionic) and nonionic dimers.
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Evaluation and Comparison
Between Visipaque (Iodixanol)
and Hexabrix (Ioxaglate)
in Coronary Angiography
We read with interest the report by Jo et al. (1). The reported
head-to-head study (RECOVER [Renal Toxicity Evaluation and
Comparison Between Visipaque and Hexabrix in Patients With
Renal Insufficiency Undergoing Coronary Angiography]) compares
the renal tolerance of the iso-osmolar contrast medium (CM) iodixa-
nol to the low-osmolar CM ioxaglate using established surrogate
definitions for contrast-induced nephropathy (CIN). Jo et al. (1)
believe the results of the RECOVER study support the conclusions of
the NEPHRIC (Nephrotoxic Effects in High-Risk Patients Under-
going Angiography) study (2), which created the hypothesis that
iso-osmolar CM are superior regarding CIN as compared to the
well-established low-osmolar contrast media (LOCM). To date, the
NEPHRIC study was never confirmed in a larger series, a fact that
has increasingly raised concerns (3).
The results of RECOVER are in complete disagreement with the
results of our recent registry analysis in over 57,000 patients (4). The
latter study clearly demonstrates a higher incidence of actual renal
failure after iodixanol application as compared to ioxaglate or iohexol
application. We note that the RECOVER study includes more
patients (n  275) than the NEPHRIC study (n  129), but taking
the reported figures of the RECOVER study at face value one cannot
fail to notice some inconsistencies in the results. The broad surrogate
definition of CIN, 25% relative or 0.5 mg/dl increase over baseline,
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